Manuela Valente Sells 2,376 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Manuela Valente sold 2,376 shares of the business’s stock in a transaction dated Tuesday, April 7th. The stock was sold at an average price of $4.87, for a total transaction of $11,571.12. Following the completion of the sale, the insider directly owned 219,275 shares of the company’s stock, valued at $1,067,869.25. The trade was a 1.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Manuela Valente also recently made the following trade(s):

• On Monday, April 6th, Manuela Valente sold 2,597 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.85, for a total transaction of $12,595.45.
• On Thursday, March 19th, Manuela Valente sold 380 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.79, for a total transaction of $1,820.20.

SOPHiA GENETICS Price Performance

SOPH opened at $4.73 on Friday. The company has a 50-day moving average of $4.76 and a 200-day moving average of $4.68. The company has a market capitalization of $323.96 million, a P/E ratio of -9.27 and a beta of 1.04. SOPHiA GENETICS SA has a 1-year low of $2.58 and a 1-year high of $5.70. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.84 and a current ratio of 1.96.

SOPHiA GENETICS (NASDAQ:SOPH) last released its earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.08). The company had revenue of $21.71 million during the quarter, compared to the consensus estimate of $21.20 million. SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%. Equities analysts expect that SOPHiA GENETICS SA will post -0.96 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. BTIG Research reissued a “buy” rating and issued a $7.00 target price on shares of SOPHiA GENETICS in a research report on Tuesday, March 3rd. Guggenheim boosted their target price on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $7.00.

Trending Headlines about SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Large institutional buying: UBS Asset Management and Akre Capital materially increased positions recently (UBS added ~5.4M shares). That sizable institutional demand can support the stock and offsets some insider selling. MarketBeat Institutional/Insider Summary
• Neutral Sentiment: Multiple senior executives (CEO Jurgi Camblong, CFO George Cardoza, CTO Abhimanyu Verma, President Ross Muken and others) executed several small sales (roughly 600–2,700 shares each) under Rule 10b5‑1 plans to cover tax withholding tied to vesting awards; these are disclosed in SEC Form 4 filings. Representative SEC filing (CEO): CEO Form 4
• Neutral Sentiment: Analyst views are mixed but skew positive: Guggenheim and BTIG have reiterated/raised targets to ~$7 with buy ratings, while one service retains a sell. Those analyst targets imply upside vs. current levels and help explain why institutional buyers remain active. Analyst Coverage
• Negative Sentiment: Collective insider selling can create short‑term downward pressure — even though each trade is small and pre‑arranged, the clustered timing (multiple execs selling within the same days) contributed to intraday selling and likely drove the price lower. Summary of the insider trade reports: InsiderTrades article

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Alta Wealth Advisors LLC acquired a new stake in shares of SOPHiA GENETICS in the third quarter valued at approximately $6,708,000. Polen Capital Management LLC bought a new stake in shares of SOPHiA GENETICS during the fourth quarter valued at approximately $102,000. Susquehanna International Group LLP bought a new stake in shares of SOPHiA GENETICS during the third quarter valued at approximately $88,000. XTX Topco Ltd bought a new stake in shares of SOPHiA GENETICS during the fourth quarter valued at approximately $55,000. Finally, Quadrature Capital Ltd bought a new stake in shares of SOPHiA GENETICS during the fourth quarter valued at approximately $54,000. Institutional investors own 31.59% of the company’s stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.